The expanded CAG repeat that causes HD sits within the very beginning of the huntingtin gene. Sometimes the huntingtin ...

A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, ...

Day 3 of #HD2026 put HTT under the microscope. Researchers shared new insights into HTT1a, next-generation HTT-lowering ...

We’re pleased to announce the 2026 HDBuzz Prize! This year, the HDBuzz Prize is brought to you by the Hereditary Disease ...

In plain language. Written by scientists. From vision changes to genetic traffic jams and a clinical trial update, May was full of HD science excitement! Dive into our latest roundup to see how ...

In plain language. Written by scientists. Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several genetic diseases, including ...

In plain language. Written by scientists. ⏱️10min read | Roche’s decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn’t end there. Years of research answered ...

In plain language. Written by scientists. #Buzzilia, day 4: Jeff and Ed's roundup of happenings from the closing day of the HD World Congress in Rio de Janeiro #Buzzilia, day 3: Jeff and Ed's roundup ...

Huntington’s disease (HD) is caused by a change in a single gene known as huntingtin. This gene contains the instructions for making the huntingtin proteinhuntingtin protein The protein produced by ...

Roche’s announcement that they were ending two of their HD programs was genuinely disappointing, and it leaves behind some unanswered questions. Was huntingtin lowered enough in the brain regions that ...